A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care

Tarec Christoffer El-Galaly; Verena I. Gaidzik; Mihnea Alexandru Gaman; Darko Antic; Jessica Okosun; Mhairi Copland; Veronika Sexl; Adele K. Fielding; Robin Doeswijk; Helen Parker; Martin Dreyling; Konstanze Döhner; António Medina Almeida; Elizabeth Macintyre; John G. Gribben; Kirsten Grønbæk

doi:10.1097/HS9.0000000000000842

A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care

Tarec Christoffer El-Galaly^*, Verena I. Gaidzik, Mihnea Alexandru Gaman, Darko Antic, Jessica Okosun, Mhairi Copland, Veronika Sexl, Adele K. Fielding, Robin Doeswijk, Helen Parker, Martin Dreyling, Konstanze Döhner, António Medina Almeida, Elizabeth Macintyre, John G. Gribben, Kirsten Grønbæk

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Leder › Forskning

12 Citationer (Scopus)

16 Downloads (Pure)

Abstract

Diversity, equity, and inclusion (DEI) in research is important. This is the case not only because it is simply the right thing to do but also because DEI fosters collaboration, empathy, and psychological safety between scientists and clinicians as well as in our attitudes to and relations with patients. Inclusion of patient samples from diverse populations is critical to ensure that the full range of biological variabilities are represented in basic and clinical research.

Originalsprog	Engelsk
Artikelnummer	e842
Tidsskrift	HemaSphere
Vol/bind	7
Udgave nummer	3
Antal sider	4
ISSN	2572-9241
DOI	https://doi.org/10.1097/HS9.0000000000000842
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
TCE-G reports previous employment at Roche (ended within 24 months) and speakers fee from AbbVie (2021). MC reports research funding from Cyclacel and Incyte, is/has been an advisory board member for Astellas, Novartis, Incyte, Jazz Pharmaceuticals, Pfizer, and Servier; and has received honoraria from Astellas, Novartis, Incyte, Pfizer, and Jazz Pharmaceuticals. MD reports research support (institution) from AbbVie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche; speakers’ honoraria from Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche; is an Editor for HemaSphere; and Scientific Advisory Board: Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis and Roche. KD reports Consulting (C)/advisory role (A)/honoraria (H), Research (R) from: AbbVie (C, H, A), Celgene/BMS (A, H, R), Janssen (H, A), Novartis (C, A, H, R), CTI BioPharma Corp (C, A, H), Roche (A, H), GSK (A, H), Astellas (R), Agios (R), JAZZ (A, H), Daichi Sankyo (A, H). JG reports grant funding from AZ, Janssen and BMS; PI of clinical trials: Abbvie, Janssen, Morphosys, Genmab, Roche, Vertex, and Lilly; and Honoraria for Advisory Boards/speaking: Abbvie, Amgen, Janssen, Kite/Gilead, and Novartis. KG reports research grant from Janssen Pharma; advisory board member GSK and Nanexa; collaboration with Novo Nordisk. All the other authors have no conflicts of interest to disclose.

Adgang til dokumentet

10.1097/HS9.0000000000000842Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 239 KBLicens: CC BY-NC-ND

Citationsformater

El-Galaly, T. C., Gaidzik, V. I., Gaman, M. A., Antic, D., Okosun, J., Copland, M., Sexl, V., Fielding, A. K., Doeswijk, R., Parker, H., Dreyling, M., Döhner, K., Almeida, A. M., Macintyre, E., Gribben, J. G., & Grønbæk, K. (2023). A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care. HemaSphere, 7(3), Artikel e842. https://doi.org/10.1097/HS9.0000000000000842

El-Galaly, TC, Gaidzik, VI, Gaman, MA, Antic, D, Okosun, J, Copland, M, Sexl, V, Fielding, AK, Doeswijk, R, Parker, H, Dreyling, M, Döhner, K, Almeida, AM, Macintyre, E, Gribben, JG & Grønbæk, K 2023, 'A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care', HemaSphere, bind 7, nr. 3, e842. https://doi.org/10.1097/HS9.0000000000000842

@article{34b7ddcfd72e49f8a4022f932c73d699,

title = "A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care",

abstract = "Diversity, equity, and inclusion (DEI) in research is important. This is the case not only because it is simply the right thing to do but also because DEI fosters collaboration, empathy, and psychological safety between scientists and clinicians as well as in our attitudes to and relations with patients. Inclusion of patient samples from diverse populations is critical to ensure that the full range of biological variabilities are represented in basic and clinical research.",

author = "El-Galaly, {Tarec Christoffer} and Gaidzik, {Verena I.} and Gaman, {Mihnea Alexandru} and Darko Antic and Jessica Okosun and Mhairi Copland and Veronika Sexl and Fielding, {Adele K.} and Robin Doeswijk and Helen Parker and Martin Dreyling and Konstanze D{\"o}hner and Almeida, {Ant{\'o}nio Medina} and Elizabeth Macintyre and Gribben, {John G.} and Kirsten Gr{\o}nb{\ae}k",

note = "Funding Information: TCE-G reports previous employment at Roche (ended within 24 months) and speakers fee from AbbVie (2021). MC reports research funding from Cyclacel and Incyte, is/has been an advisory board member for Astellas, Novartis, Incyte, Jazz Pharmaceuticals, Pfizer, and Servier; and has received honoraria from Astellas, Novartis, Incyte, Pfizer, and Jazz Pharmaceuticals. MD reports research support (institution) from AbbVie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche; speakers{\textquoteright} honoraria from Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche; is an Editor for HemaSphere; and Scientific Advisory Board: Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis and Roche. KD reports Consulting (C)/advisory role (A)/honoraria (H), Research (R) from: AbbVie (C, H, A), Celgene/BMS (A, H, R), Janssen (H, A), Novartis (C, A, H, R), CTI BioPharma Corp (C, A, H), Roche (A, H), GSK (A, H), Astellas (R), Agios (R), JAZZ (A, H), Daichi Sankyo (A, H). JG reports grant funding from AZ, Janssen and BMS; PI of clinical trials: Abbvie, Janssen, Morphosys, Genmab, Roche, Vertex, and Lilly; and Honoraria for Advisory Boards/speaking: Abbvie, Amgen, Janssen, Kite/Gilead, and Novartis. KG reports research grant from Janssen Pharma; advisory board member GSK and Nanexa; collaboration with Novo Nordisk. All the other authors have no conflicts of interest to disclose.",

year = "2023",

doi = "10.1097/HS9.0000000000000842",

language = "English",

volume = "7",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Lippincott, Williams & Wilkins",

number = "3",

}

TY - JOUR

T1 - A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care

AU - El-Galaly, Tarec Christoffer

AU - Gaidzik, Verena I.

AU - Gaman, Mihnea Alexandru

AU - Antic, Darko

AU - Okosun, Jessica

AU - Copland, Mhairi

AU - Sexl, Veronika

AU - Fielding, Adele K.

AU - Doeswijk, Robin

AU - Parker, Helen

AU - Dreyling, Martin

AU - Döhner, Konstanze

AU - Almeida, António Medina

AU - Macintyre, Elizabeth

AU - Gribben, John G.

AU - Grønbæk, Kirsten

N1 - Funding Information: TCE-G reports previous employment at Roche (ended within 24 months) and speakers fee from AbbVie (2021). MC reports research funding from Cyclacel and Incyte, is/has been an advisory board member for Astellas, Novartis, Incyte, Jazz Pharmaceuticals, Pfizer, and Servier; and has received honoraria from Astellas, Novartis, Incyte, Pfizer, and Jazz Pharmaceuticals. MD reports research support (institution) from AbbVie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche; speakers’ honoraria from Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche; is an Editor for HemaSphere; and Scientific Advisory Board: Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis and Roche. KD reports Consulting (C)/advisory role (A)/honoraria (H), Research (R) from: AbbVie (C, H, A), Celgene/BMS (A, H, R), Janssen (H, A), Novartis (C, A, H, R), CTI BioPharma Corp (C, A, H), Roche (A, H), GSK (A, H), Astellas (R), Agios (R), JAZZ (A, H), Daichi Sankyo (A, H). JG reports grant funding from AZ, Janssen and BMS; PI of clinical trials: Abbvie, Janssen, Morphosys, Genmab, Roche, Vertex, and Lilly; and Honoraria for Advisory Boards/speaking: Abbvie, Amgen, Janssen, Kite/Gilead, and Novartis. KG reports research grant from Janssen Pharma; advisory board member GSK and Nanexa; collaboration with Novo Nordisk. All the other authors have no conflicts of interest to disclose.

PY - 2023

Y1 - 2023

N2 - Diversity, equity, and inclusion (DEI) in research is important. This is the case not only because it is simply the right thing to do but also because DEI fosters collaboration, empathy, and psychological safety between scientists and clinicians as well as in our attitudes to and relations with patients. Inclusion of patient samples from diverse populations is critical to ensure that the full range of biological variabilities are represented in basic and clinical research.

AB - Diversity, equity, and inclusion (DEI) in research is important. This is the case not only because it is simply the right thing to do but also because DEI fosters collaboration, empathy, and psychological safety between scientists and clinicians as well as in our attitudes to and relations with patients. Inclusion of patient samples from diverse populations is critical to ensure that the full range of biological variabilities are represented in basic and clinical research.

U2 - 10.1097/HS9.0000000000000842

DO - 10.1097/HS9.0000000000000842

M3 - Editorial

C2 - 36844176

AN - SCOPUS:85148769853

SN - 2572-9241

VL - 7

JO - HemaSphere

JF - HemaSphere

IS - 3

M1 - e842

ER -